Prostate Cancer International is
for 2011 by Great NonProfits
The April issue of the Journal of the Canadian Urologic Association offers the interested reader access to the full texts of a small number of topical articles. None of them could be considered “game changing” in terms of current prostate cancer management today … but certainly thought-stimulating.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: adjuvant, biopsy, Diagnosis, Prevention, radiation, risk, salvage | Leave a Comment »
According to an announcement from the European Association for Urology (EAU) earlier today, data from a recently completed trial demonstrate that degarelix is “non-inferior” to the LHRH agonist goserelin acetate + the antiandrogen bicalutamide at reducing prostate volume in men with advanced hormone- dependent prostate cancer.
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, Degarelix, neoadjuvant, radiation therapy | 2 Comments »
In the October issue of European Urology there was an interesting “consensus statement” about the role of radiation therapy as adjuvant or salvage therapy for men who are at significant risk for recurrence of their prostate cancer after first-line treatment with radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", adjuvant, post-surgery, radiation therapy, salvage | 1 Comment »
A new study just published in BJU International offers data suggesting the idea that all men found to have positive seminal vesicles (SV+) after radical prostatectomy should receive immediate adjuvant treatment with external beam radiation and androgen deprivation therapy (ADT).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, androgen deprivation, positive, radiation therapy, seminal vesicle | 21 Comments »
There are no absolute guidelines as to which patients who have positive surgical margins after a radical prostatectomy (RP) are most appropriate for immediate adjuvant radiation therapy (with or without neoadjuvant and/or adjuvant hormone therapy).
Filed under: Management, Treatment | Tagged: adjuvant, margin, outcome, positive, radiation, radical prostatectomy | 3 Comments »
As we first reported in March 2010, when data were originally presented at the Genitourinary Cancers Symposium, RTOG 94-08 has shown that 4 months of androgen deprivation therapy (ADT) before and during external beam radiation therapy (EBRT) reduces the overall and the prostate cancer-specific mortality rates for men with localized prostate cancer (clinical stages T1b, [...]
Filed under: Management, Treatment | Tagged: adjuvant, ADT, androgen deprivation, EBRT, mortality, neoadjuvant, outcome, radiation therapy, RTOG 94-08 | Leave a Comment »
A recent study published in “The Red Journal” suggests (perhaps not surprisingly) that radiation oncologists and urologists have different mindsets about the application of immediate adjuvant radiation therapy following surgery for prostate cancer patients with a variety of adverse pathologic risk factors.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, radiation, salvage, second-line | 7 Comments »
Back in June 2010, we reported on the initial results of SWOG 9921 — a trial that randomized 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", adjuvant, ADT, androgen deprivation therapy, surgery | 6 Comments »
Over 200 posters and other presentations of new data, as well as many other discussions and lectures, were offered yesterday in the prostate cancer sessions at the Genitourinary Cancers Symposium in Orlando.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Treatment | Tagged: adjuvant, ADT, bicalutamide, CyberKnife, dutasteride, intermittent, pomegranate, SBRT, screening | 1 Comment »
New data published by clinical researchers at the Mayo Clinic have suggested that there is no overall survival benefit associated with adjuvant hormone therapy after surgery in men with pathological T3b disease.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, hormone therapy, post-surgery, pT3b | 9 Comments »
Men with high-risk, localized prostate cancer who decide on surgery as their first-line treatment of choice are sometimes faced with the question of whether to undergo “immediate” adjuvant radiation therapy after their surgery or to do nothing and wait to see if salvage radiation therapy becomes necessary.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: adjuvant, outcome, prostatectomy, radiation, salvage | Leave a Comment »
In March 2009, Thompson et al. published data from the SWOG 8794 trial showing that adjuvant radiation therapy immediately post-surgery significantly improved the oncologic outcomes of men with pathologic T3N0M0 prostate cancer compared to later salvage radiation, but
Filed under: Management, Treatment | Tagged: adjuvant, post-surgery, radiation, salvage, surgical margins, T3 disease | 4 Comments »
The use of androgen deprivation therapy (ADT) is at the heart of treatment for patients with advanced forms of prostate cancer. What has been debated for years, however, is when, for how long, and in combination with what other forms of therapy ADT should be applied.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, androgen deprovation therapy, local therapy, locally advanced, outcome | 9 Comments »
Over the years, several randomized trials have shown the benefit of combining androgen deprivation therapy (ADT) with radiation therapy (RT) for the first- and second-line treatment of men with prostate cancer. However,
Filed under: Management, Treatment | Tagged: adjuvant, ADT, androgen deprivation therapy, outcome, radiation trerapy | 13 Comments »
A number of trials are currently evaluating the potential value of adjuvant chemotherapy after first-line treatment in men with high-risk prostate cancer. The effects of this form of treatment on long-term outcomes still to be established, but …
Filed under: Management, Treatment | Tagged: "high risk", adjuvant, chemotherapy, paclitaxel | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site